Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer

[1]  E. Yang,et al.  Beyond DNA Repair: Additional Functions of PARP-1 in Cancer , 2013, Front. Oncol..

[2]  A. Chinnaiyan,et al.  Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. , 2013, Neoplasia.

[3]  T. Lawrence,et al.  Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair , 2013, Clinical Cancer Research.

[4]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Fangmei Liu,et al.  Poly(ADP-ribose) polymerase 1 is a key regulator of estrogen receptor α-dependent gene transcription. , 2013, The Journal of biological chemistry.

[6]  A. Chinnaiyan,et al.  Dual roles of PARP-1 promote cancer growth and progression. , 2012, Cancer discovery.

[7]  Stewart J Anderson,et al.  Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Reddy,et al.  Modern outcomes of inflammatory breast cancer. , 2012, International Journal of Radiation Oncology, Biology, Physics.

[9]  J. Bartek,et al.  Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment , 2012, Cell cycle.

[10]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[11]  J. Carroll,et al.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? , 2012, Molecular endocrinology.

[12]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[13]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[14]  E. Kohn,et al.  Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Knopp,et al.  A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[17]  P. Glazer,et al.  Abstract 3893: Mechanism of radiosensitization by inhibitors of poly(ADP-ribose) polymerase (PARP) , 2011 .

[18]  J. Doroshow,et al.  Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201 , 2011 .

[19]  P. Glazer.  Mechanism of Radiosensitization by Inhibitors of Poly (ADP-Ribose) Polymerase (PARP) , 2010 .

[20]  S. Bhide,et al.  Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. , 2010, Cancer treatment reviews.

[21]  C. Barker,et al.  Enhancing radiotherapy through a greater understanding of homologous recombination. , 2010, Seminars in radiation oncology.

[22]  Alan Ashworth,et al.  Translating cancer research into targeted therapeutics , 2010, Nature.

[23]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[24]  Hans Clevers,et al.  Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines , 2010, Breast Cancer Research and Treatment.

[25]  N. Curtin,et al.  Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation. , 2009, International journal of radiation oncology, biology, physics.

[26]  D. Sgroi,et al.  Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies , 2009, Molecular Cancer Research.

[27]  J. Klijn,et al.  Low-risk susceptibility alleles in 40 human breast cancer cell lines , 2009, BMC Cancer.

[28]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  David H. Johnson,et al.  Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models , 2007, Clinical Cancer Research.

[30]  Eric F. Johnson,et al.  ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.

[31]  A. Yasui,et al.  RAD18 and Poly(ADP-Ribose) Polymerase Independently Suppress the Access of Nonhomologous End Joining to Double-Strand Breaks and Facilitate Homologous Recombination-Mediated Repair , 2007, Molecular and Cellular Biology.

[32]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[33]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[34]  C. Glass,et al.  A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription , 2006, Science.

[35]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.

[36]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[37]  Seiichiro Yamamoto,et al.  Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.

[38]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[39]  T. Pawlik,et al.  Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[40]  B. Marples,et al.  PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. , 2004, International journal of radiation oncology, biology, physics.

[41]  N. Curtin,et al.  Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. , 2003, Cancer research.

[42]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[43]  E. Wilkinson.  Cancer Research UK , 2002 .

[44]  G. Hortobagyi,et al.  Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  V. Schreiber,et al.  Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. , 2000, Biochemistry.

[46]  J. Haber.  DNA recombination: the replication connection. , 1999, Trends in biochemical sciences.

[47]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Sutherland,et al.  MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. , 1994, European journal of cancer.

[49]  M. Dumont,et al.  Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. , 1989, Endocrinology.

[50]  B. Fertil,et al.  Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. , 1984, Radiation research.